Publications
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
November 12, 2021
COM701 in combination with BMS-986207 (anti-TIGIT antibody) and nivolumab – preliminary results of safety, tolerability and pharmacokinetics in patients with advanced solid tumors (video)
Ecaterina Elena Dumbrava, et al, SITC 2021 annual meeting
June 8, 2021
COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716)
Daniel A. Vaena, et al, ASCO Annual Meeting
April 27, 2020
COM701 Demonstrates Antitumor Activity as Monotherapy and in Combination with Nivolumab in Patients with Advanced Malignancies
Ryan Sullivan, et al, AACR Annual Meeting
February 6, 2020
A Phase 1 Study Evaluating COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Malignancies
RJ Sullivan, et al, ASCO-SITC Clinical Immuno-Oncology Symposium
November 9, 2019
Phase 1 Study of COM701 Monotherapy and in Combination with Nivolumab in Patients with Advanced Solid Tumors
E. Ileana Dumbrava, et al, SITC Annual Meeting
November 8, 2019
Phase 1 Study of The Safety, Tolerability and Preliminary Anti Tumor Activity of COM701 Monotherapy in Patients with Advanced Solid Tumors
E. Ileana Dumbrava, et al, SITC Annual Meeting
September 19, 2019
COM701 (A Novel Immune Checkpoint Inhibitor) in Patients with Advanced Solid Tumors
A. ElNaggar, et al, International Gynecologic Cancer Society (IGCS) Annual Global Meeting
June 1, 2019
A Phase 1 Study Evaluating COM701 in Patients with Advanced Solid Tumors
Drew W. Rasco, et al, ASCO Annual Meeting
April 2, 2019
Phase I Study of COM701 (a novel checkpoint inhibitor of PVRIG) in Patients with Advanced Solid Tumors (trial-in-progress poster abstract)
Dan Vaena, et al, AACR Annual Meeting
